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CD163-L1 Is an Endocytic Macrophage Protein Strongly
Regulated by Mediators in the Inflammatory Response
Jesper B. Moeller,* Marianne J. Nielsen,† Martin P. Reichhardt,* Anders Schlosser,*
Grith L. Sorensen,* Ole Nielsen,‡ Ida Tornøe,* Jørn Grønlund,* Maria E. Nielsen,*
Jan S. Jørgensen,x Ole N. Jensen,{ Jan Mollenhauer,* Søren K. Moestrup,† and
Uffe Holmskov*
CD163-L1 belongs to the group B scavenger receptor cysteine-rich family of proteins, where the CD163-L1 gene arose by dupli-
cation of the gene encoding the hemoglobin scavenger receptor CD163 in late evolution. The current data demonstrate that CD163-
L1 is highly expressed and colocalizes with CD163 on large subsets of macrophages, but in contrast to CD163 the expression is low or
absent in monocytes and in alveolar macrophages, glia, and Kupffer cells. The expression of CD163-L1 increases when cultured
monocytes areM-CSF stimulated to macrophages, and the expression is further increased by the acute-phase mediator IL-6 and the
anti-inflammatory mediator IL-10 but is suppressed by the proinflammatory mediators IL-4, IL-13, TNF-a, and LPS/IFN-g.
Furthermore, we show that CD163-L1 is an endocytic receptor, which internalizes independently of cross-linking through a cla-
thrin-mediated pathway. Two cytoplasmic splice variants of CD163-L1 are differentially expressed and have different subcellular
distribution patterns. Despite its many similarities to CD163, CD163-L1 does not possess measurable affinity for CD163 ligands
such as the haptoglobin–hemoglobin complex or various bacteria. In conclusion, CD163-L1 exhibits similarity to CD163 in terms
of structure and regulated expression in cultured monocytes but shows clear differences compared with the known CD163 ligand
preferences and expression pattern in the pool of tissue macrophages. We postulate that CD163-L1 functions as a scavenger
receptor for one or several ligands that might have a role in resolution of inflammation. The Journal of Immunology, 2012, 188:
2399–2409.
C
D163-L1 (M160) is a group B scavenger receptor cys-
teine-rich (SRCR) molecule that is expressed by cells
of myeloid origin (1). CD163-L1 belongs to the SRCR
superfamily, which is an ancient group of receptors that have been
identified in a wide range of animal phyla and in certain unicel-
lular algae (2–4). The domain organization of CD163-L1 features
a large extracellular region containing 12 group B SRCR domains,
followed by a transmembrane region and a cytoplasmic tail that
occurs in two forms: the predominant full-length variant CD163-
L1a of 71 residues and the short-tail variant CD163-L1b of 39
residues.
We have previously shown by conventional RT-PCR that
CD163-L1mRNA is expressed by alveolar macrophages and by the
myeloid cell lines HL60, U937, and THP1 but not by Jurkat or
Raji cells. Moreover, stimulation of U937 cells with phorbol ester
resulted in an increase of expression. RT-PCR analysis of 19
different tissues showed that the full-length CD163-L1a is ex-
pressed in all tissues, whereas expression of CD163-L1b appears
confined to the spleen (1).
The five membrane-proximal SRCR domains of CD163-L1
constitute a so-called long-range repeat, which shows up to 75%
sequence identity to that of CD163 (1, 5). The high structural
similarity to CD163, together with the assignment of the gene
encoding CD163-L1 to chromosome 12p13.3 adjacent to the
CD163 gene, suggests that the primate-specific CD163-L1 has
emerged via a recent gene duplication of CD163 (1, 6).
CD163 is a well-characterized transmembrane glycoprotein
that comprises nine extracellular SRCR group B domains, followed
by a transmembrane region and a cytoplasmic tail that occurs in
three forms (7). CD163 has been identified and characterized as
an endocytic receptor for the haptoglobin–hemoglobin (Hp–Hb)
complex and is believed to be essential for the removal of free
hemoglobin by macrophages during hemolysis (8–10). In addi-
tion, CD163 has also been identified as a potential erythroblast
adhesion receptor and as a novel pattern recognition receptor for
bacteria (11, 12). Indeed, the ability to bind microbial micro-
organisms has been shown for several members of the SRCR
superfamily including SR-AI, gp-340, MARCO, CD5, CD6, and
Spa, suggesting a possible unifying function as pattern recogni-
tion receptors in host defense (13–18).
At present, little is known about the expression and function of
CD163-L1. In the current study, we have developed and used novel
Abs directed against the protein for characterization of the CD163-
L1 tissue distribution and regulation. Moreover, we have used
various recombinant protein expression approaches to study the
endocytic properties of CD163-L1 and potential differences of two
splice variants of the protein.
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Buffers used were PBS (137mMNaCl, 3 mMKCl, 8 mMNa2HPO4, 1.5 mM
KH2PO4, pH 7.4), PBS/BSA [PBS, 0.5% (w/v) BSA], TBS [140 mM NaCl,
10 mM Tris-HCl, 0.02% (w/v) NaN2, pH 7.4], TBST (TBS, 0.05%
Tween 20), sample buffer (100 mM Tris, 2% SDS, 10% glycerol, 0.0145%
bromophenol blue, pH 8.9), and TEG buffer (10 mM Tris, 0.5 mM EDTA,
pH 9).
Establishment of stable transfectant cells
HEK293 cells transfected with CD163 cDNAwere obtained from a previous
study (19), and vectors containing CD163-L1a or CD163 cDNA (1, 8) were
used as templates for the generation of all other constructs. Full-length
CD163-L1b cDNA was obtained by PCR mutagenesis of the CD163-L1a
cDNA using the 59-phosphorylated primers 59P-GATGACACCCCCAA-
CCATGGTTGTGAAGATGC-39 and 59P-TCTGAGGGGCAGATGTTTTT-
GTTTCTGAACTC-39. Mutagenesis of the di-leucine internalization motif
of CD163-L1a was performed using the QuickChange II Site-Directed
Mutagenesis Kit according to the manufacturer’s recommendations
(Stratagene). cDNA fragments of the CD163-L1 splice variants, CD163-L1
SRCR 1–7, and CD163-L1 ectodomain were produced by PCR using the
forward primer CD163-L1FL 59-GACTCAGGAAGAGATAGACC-39 and the
corresponding reverse primers CD163-L1 FL 59-GGACAAGTTTTCCA-
TAGG-39, CD163-L1 SRCR 1–7 59-AATCTGCCTGTGGGCTGAGCA-39,
and CD163-L1 ectodomain 59-CAGCGACTGTCCAGAGCACCT-39,
respectively. The PCR products were cloned into the expression vector
pcDNA5/FRT/V5-His-TOPO TA vector (Invitrogen) and sequenced in
their entirety. The fusion construct encoding the extracellular and trans-
membrane regions of CD163 (aa 1–1067) fused to the cytoplasmic tail
of CD163-L1 (aa 1383–1453) was generated by PCR using the CD163
primers 59-CCCGGTACCGAATTCTTAGTTGTTTTC-39 and 59-CCC-
GGATCCAGTCAAGAAGAATAATGC-39 and the CD163-L1 primers
59-GAGTCTGGATCCTGCCGAGTTCAGAAACAAAAAC-39 and 59-
GAGGAGGCGGCCGCTTGGACAAGTTTTCCATAGGGC-39. The gen-
erated cDNA fragments were inserted into the KpnI and NotI sites of the
pcDNA5/FRT vector, respectively, and fused to one another by ligation,
taking advantage of a primer-generated BamHI site situated in the 39 end
of the CD163 cDNA fragment and 59 end of the CD163-L1 cDNA frag-
ment. The resulting fusion construct was sequenced in its entirety. The
produced pcDNA5/FRT vectors were transfected into Flp-In HEK293 cells
(Invitrogen) using either jetPEI (Polyplus-transfection) or FuGENE
6 (Roche Diagnostics). Stable transfectants were selected with 150 mg/ml
Hygromycin B (Invitrogen), and protein expression was verified by
Western blotting of cell culture supernatants or cell lysates. Stably trans-
fected clones were cultured and maintained in DMEM, 2 mM L-glutamine,
10% FBS, 150 mg/ml Hygromycin B, 100 U/ml penicillin, and 100 mg/ml
streptomycin (Invitrogen).
Expression and purification of recombinant CD163-L1
Stably transfected clones expressing recombinant CD163-L1 SRCR 1–7 or
ectodomain were grown to confluence. At confluence, cells were washed
three times in PBS and cultured without FBS in DMEM, 2 mM L-gluta-
mine, 20 U/ml penicillin, and 20 mg/ml streptomycin (Invitrogen).
Supernatants were harvested after 96 h, and recombinant CD163-L1 SRCR
1–7 and ectodomain were purified using a HisTrap HP column (GE
Healthcare) as described by Schlosser et al. (20).
Development of mAbs
BALB/c mice were immunized s.c. with 25 mg purified recombinant
CD163-L1 SRCR 1–7 in 400 ml 1:1 (v/v) PBS/Freund’s incomplete ad-
juvant per injection. The injections were repeated at intervals of 14 d. Mice
with high Ab titer against CD163-L1, as determined by ELISA on CD163-L1
SRCR 1–7 coated microtiter plates, were selected for fusion with spleen
cells. B cell hybridomas were produced by fusion with myeloma cells
(X63Ag8.6.5.3) using polyethylene glycol 4000 as the fusogen. Recombinant
CD163-L1 SRCR 1–7 was used to identify positive anti–CD163-L1 clones
by ELISA. Hybridomas producing Abs against CD163-L1 were cloned three
times and adapted to serum-free hybridoma medium containing 20 units/ml
penicillin and 20 mg/ml streptomycin (Invitrogen). Abs were purified using
a protein G column (GE Healthcare) as described by Schlosser et al. (20).
ELISA and biotinylation of Abs were performed essentially as described by
Leth-Larsen et al. (21).
Generation of Fab
Purified mAbs were dialyzed against 100 mM acetate buffer, 1 mM EDTA,
and 50 mM cysteine pH 5.5 and incubated for 5 h with 10 mg/mg (Ab) of
papain (Sigma-Aldrich). The generated Fab fragments were separated
by size exclusion chromatography using PBS pH 7.4 on a Superdex 200
HiLoad 16/60 column (GE Healthcare).
Immunoprecipitation of CD163-L1
mAbs were immobilized using cyanogen bromide-activated Sepharose 4B
(GE Healthcare). Coupling was performed as recommended by the man-
ufacturer using 10mgAb per milliliter of gel. The monoclonal anti-OVAAb
(Hyb 099-01) was used as a control. Immunoprecipitation was performed
using Triton X-100 lysates of placenta precleared against Sepharose 4B
(GE Healthcare) for 1 h at 4˚C. In brief, 200 ml Sepharose 4B-immobilized
Ab slurry was combined with 10 ml placenta lysate and incubated for 2 h
at 4˚C with gentle agitation. The immobilized Ab matrices were washed
twice in 10 ml lysis buffer and twice in 10 ml TBS containing 500 mM
NaCl and 5 mM CaCl2. Elution was performed using 100 mM glycine
HCl, pH 2.7.
Alexa Fluor 488 labeling of Abs
Alexa Fluor 488 labeling of mAbs and Fab fragments was performed using
the Alexa Fluor protein labeling kit, as described by the manufacturer
(Invitrogen).
SDS-PAGE and Western blotting
Protein samples were diluted in sample buffer, denatured, and separated on
4–12% polyacrylamide gradient gels using a discontinuous buffer system
(Bio-Rad). Separated proteins were blotted onto Amersham Hybond-P
polyvinylidene difluoride membranes (GE Healthcare). The membranes
were incubated overnight at 4˚C with 1 mg/ml monoclonal mouse anti–
CD163-L1 (HG-Hyb1-3), polyclonal rabbit anti–CD163-L1 (Protein Atlas
ID: HPA015663), polyclonal rabbit anti-CD163 Ab (8) or polyclonal rabbit
anti–gp-340 (22) diluted in TBST containing 2.5% (w/v) dry milk. The
membrane was washed extensively in TBST and incubated for 1 h in TBST
with either alkaline phosphatase-coupled rabbit anti-mouse IgG (Sigma-
Aldrich) diluted 1:2000, HRP-coupled goat anti-rabbit IgG (Sigma-Aldrich)
diluted 1:10,000, or HRP-coupled rabbit anti-mouse IgG (Sigma-Aldrich)
diluted 1:10,000. The membranes were washed extensively and developed
as described by Schlosser et al. (20) or using the ECL Plus kit, as described
by the manufacturer (GE Healthcare).
Deglycosylation of CD163-L1
Deglycosylation of CD163-L1 expressed by HEK293 cells was performed
by enzymatic digestion with PNGase F (unreduced), as recommended by
the manufacturer (New England Biolabs).
Quantification of gene expression by real-time PCR
The relative tissue distribution of CD163-L1 mRNA was analyzed using
a commercial cDNA library (PrimerDesign). Total RNA from cultured cells
was prepared using TRIzol reagent, as recommended by the manufacturer
(Invitrogen). cDNA synthesis was performed from 1 mg purified RNA using
an oligo(dT)18 primer and the Superscript III reverse transcriptase according
to the manufacturer’s recommendations (Invitrogen). Relative quantification
of CD163-L1 and CD163 gene expression was achieved using custom-made
TaqMan assays with the primer sequences CD163-L1exon19 (forward)
59-GCCTCTGAAGCCACAAAATGAC-39, CD163-L1 exon19 (reverse)
59-TCCTCTTTATTCATTTAAAAGTTGTTGTCTCCT-39, CD163 exon5
(forward) 59-TGAAGATGCTGGCGTGACA-39, and CD163 exon5 (re-
verse) 59-CACACCTTCCCTAACAGTCTCT-39 (Applied Biosystems).
Analysis was performed in triplicate using the cycling conditions 50˚C for
2 min and 95˚C for 10 min, followed by 40 cycles of 95˚C for 15 s and 60˚
C for 1 min. Quantification of CD163-L1a and CD163-L1b was performed
using custom-made PerfectProbe assays with the primer sequences CD163-
L1a (forward) 59-TCAGAGTTTCAACCAGAAGGAG-39, CD163-L1a
(reverse) 59-TGTCATCTGAGGTTCTTGTCC-39, CD163-L1b (forward)
59-TGCCCCTCAGAGATGACAC-39, and CD163-L1b (reverse) 5´-AGG-
TTGATCTGGTGAGCCC-39 (PrimerDesign). Analysis was performed in
triplicate using the cycling conditions 95˚C for 10 min, followed by
50 cycles of 95˚C for 15 s, 60˚C for 30 s, and 72˚C for 15 s. A standard
curve was included in each run prepared from dilution series of commercial
assay specific copy number controls (PrimerDesign). The absolute and
relative abundance of the CD163-L1 splice variants was quantified by
normalization to the measured standard curves. All studies were performed
on a 7500 Real-Time PCR System (Applied Biosystems) using 18S RNA
(tissue distribution) or the reference genes GAPDH, B2M, and TBP (cul-
tured cells) for normalization. The relative expression was analyzed using
the qBase software (Biogazelle), and the results were assessed with the
two-tailed Student t test.
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Normal human tissues were obtained from the tissue bank at the Depart-
ment of Pathology, Odense University Hospital (Odense, Denmark). Four-
micrometer parallel tissue sections were cut from neutral-buffered
formaldehyde-fixed paraffin blocks, mounted on ChemMate Capillary
Gap slides (Dako), de-paraffinated, and hydrated by conventional methods.
Endogenous peroxidase activity was blocked using TBS containing 1.5%
hydrogen peroxide for 10 min. Ag retrieval was performed by microwave
heating in TEG buffer. Three Tissue-Tek containers (Miles), each with
24 slides in 250 ml buffer, were placed on the edge of a turntable inside the
microwave oven. Slides were heated 11 min at full power (900 W), then for
15 min at 400 W. After heating, slides remained in the TEG buffer for
15 min. Immunostaining was automated using a TechMate 500 autostainer
(Dako). Detection of CD163-L1 was performed using the PowerVision+
HRP detection system DPVB+500HRP (ImmunoVision Technologies),
and immunostaining of CD163, CD11c, and CD68 was performed using
the EnVision+ HRP detection system K4001 (Dako). Incubation was
performed for 1 h at room temperature using Dako REAL Ab Diluent
(Dako) and the following Abs: 1 mg/ml monoclonal mouse anti-human
CD163-L1 (HG-Hyb1-3), 0.6 mg/ml affinity-purified polyclonal rabbit
anti-human CD163-L1 (Protein Atlas), 0.2 mg/ml anti-CD163 clone 10D6
(Novocastra), 2.7 mg/ml anti-CD11c clone 5D11 (Novocastra) or 0.1 mg/ml
anti-CD68 clone PG-M1 (Dako). Tissue sections were counterstained with
Mayer’s hematoxylin for 2 min and mounted with Aquatex (Merck). The
local ethical committee in Odense approved the use of the human tissue
sections (Ref. No. VF20050070).
Isolation and culture of human monocytes
Human peripheral blood monocytes were isolated from normal donor buffy
coats by density gradient purification followed by CD14+ selection. In brief,
buffy coats were diluted 1:1 in sterile PBS containing 2 mM EDTA
before lymphocytes were isolated over Ficoll-Paque Plus (GE Healthcare)
at 800 3 g for 20 min at room temperature. Isolated lymphocytes were
washed twice to remove platelets and suspended in PBS, 2% heat-
inactivated FBS, and 1 mM EDTA. Monocytes were isolated from the
total lymphocyte population using a CD14+ selection kit according to the
manufacturer’s recommendations (StemCell Technologies). Purified CD14+
monocytes (.98% pure, as determined by FACS analysis) were seeded in
6-well culture dishes (TPP) at a density of 1.5 3 105 cells/cm2. Macro-
phages were obtained by culturing monocytes for 7 d in RPMI 1640, 2 mM
L-glutamine, 10% heat-inactivated FBS, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 50 mM 2-mercaptoethanol (Invitrogen) supplemented
with 100 ng/ml M-CSF (Immunotools). Dendritic cells were obtained by
culturing monocytes for 6 d, substituting M-CSF with 100 ng/ml GM-CSF
and 20 ng/ml IL-4 (Immunotools). Cells were cultured in 5% CO2 in air at
37˚C. Fresh media supplemented with M-CSF or GM-CSF/IL-4 was added
at day 3. Stimulation of the generated macrophages was performed for 24 h
using either 20 ng/ml IL-4, IL-6, IL-10, IL-13, IFN-g, TNF-a (Immuno-
tools), 100 ng/ml Escherichia coli serotype 0111:B4 LPS, or 40 ng/ml
dexamethasone (Sigma-Aldrich).
Flow cytometry
All measurements of fluorescence intensity were determined on a FACS-
Calibur flow cytometer (BD Biosciences). Collected data were analyzed
using the FlowJo software (Tree Star). The isotype control (IgG1) anti-OVA
Ab (Hyb 099-01) was used in all experiments. Staining of cells was per-
formed as follows.
Peripheral blood leukocytes. Blood from healthy volunteers was collected
and diluted 1:1 (v/v) in PBS. Removal of erythrocytes was performed using
a standard hyposmolar lysis protocol. Approximately 106 cells were
resuspended in 200 ml PBS/BSA and incubated with 10 mg mAb (HG-
Hyb1-1 or HG-Hyb1-3) for 2 h at 4˚C. Cells were washed twice in PBS/
BSA and subsequently stained for 1 h at 4˚C with FITC-conjugated
polyclonal F(ab9)2 goat anti-mouse Ig (Dako) diluted 1:20. The cells
were washed three times in PBS/BSA before analysis.
Subcellular distribution of CD163-L1. HEK293 cells were detached using
Alfazyme (PAA Laboratories), washed, and suspended in PBS/BSA prior
to the experiments. Surface expression of CD163-L1a and CD163-L1b
was determined as described for peripheral blood leukocytes. The total
subcellular distribution of CD163-L1a and CD163-L1b was determined
as follows: Cells were washed twice in PBS and fixed for 20 min in
PBS containing 2% paraformaldehyde. After fixation, the cells were
permeabilized for 10 min using PBS/BSA containing 0.5% saponin.
Staining was performed essentially as described for peripheral blood
leukocytes except for the addition of 0.2% saponin to all incubation
buffers.
Internalization of CD163-L1. HEK293 cells expressing CD163-L1a were
detached using Alfazyme (PAA Laboratories), resuspended in media, and
stained for 2 h at 4˚C using unlabeled or Alexa 488-conjugated HG-Hyb1-
3 (IgG and Fab). Cells were washed twice in media before incubation was
continued at 37˚C. At time intervals (0–20 min), cells were removed and
kept on ice before cells stained with unlabeled HG-Hyb1-3 were stained
for 1 h at 4˚C with FITC-conjugated polyclonal F(ab9)2 goat anti-mouse Ig
(Dako) diluted 1:20. The cells were finally washed three times in PBS/
BSA before analysis.
Confocal microscopy
HEK293 cells were seeded on coverslips (Hounisen) at a density of 13 105
cells/coverslip 48 h prior to the experiments.
Surface distribution of CD163-L1. For the surface staining experiments,
living cells were incubated in media containing 20 mg/ml CD163-L1 mAb
(HG-Hyb1-1) for 2 h at 4˚C. Cells were washed three times in PBS and
fixed for 20 min in PBS containing 2% paraformaldehyde. Cells were
washed three times in PBS/BSA and incubated for 1 h at room temperature
with Alexa 488-conjugated F(ab9)2 goat anti-mouse IgG (Invitrogen)
diluted 1:200. Cells were washed three times in PBS, counterstained with
0.2 mM DAPI (Invitrogen), washed twice in PBS, and mounted using
ProLong Gold antifade reagent (Invitrogen).
Surface distribution of CD163 and the CD163–CD163-L1 fusion. Surface
staining of cells transfected with CD163 and the CD163–CD163-L1 fusion
was performed on coverslips essentially as described by Nielsen et al. (23)
using 10 mg/ml rabbit polyclonal anti-CD163 Ab (8) and Alexa 488-
conjugated secondary goat anti-rabbit IgG (Invitrogen) as the primary and
secondary Abs, respectively. Coverslips were mounted using Prolong Gold
antifade reagent with DAPI (Invitrogen).
Total cellular distribution of CD163-L1. The total cellular distribution of
CD163-L1 was visualized on cells fixed and permeabilized prior to staining.
Living cells were washed twice in PBS, fixed for 20 min in PBS containing
2% paraformaldehyde, and permeabilized using PBS/BSA containing 0.5%
saponin for 10 min. Fixed and permeabilized cells were stained for 1 h
at room temperature using 20 mg/ml CD163-L1 mAb (HG-Hyb1-1) in
PBS/BSA containing 0.2% saponin. Staining with Alexa 488-conjugated
F(ab9)2, DAPI staining, and mounting of the slides was performed essen-
tially as previously described except for the addition of 0.2% saponin to all
buffers.
Internalization of CD163-L1. Visualization of internalization was per-
formed using living cells incubated in media containing 20 mg/ml Alexa
488-conjugated mAb or Fab (HG-Hyb1-3) for 2 h at 4˚C. The cells were
washed twice before incubation was continued for 20 min at either 37˚C or
4˚C. Cells were washed twice in PBS and fixed for 20 min in PBS con-
taining 2% paraformaldehyde. Cells were washed twice, then counter-
stained for 10 min with 5 mg/ml Alexa 633-conjugated wheat germ
agglutinin (Invitrogen) before being stained with DAPI and mounted as
previously described. Analysis of immunostained cells was performed
using an Olympus FV1000 confocal microscope.
Endocytosis of 125I-labeled Hp–Hb
For endocytosis analysis with radiolabeled ligand, complexes of Hp(2-2)
and Hb A0 (both from Sigma) were labeled with [
125I] using the chlo-
ramine-T method. Untransfected HEK293 cells and HEK293 cells trans-
fected with CD163, CD163-L1, or CD163–CD163-L1 fusion cDNA were
seeded in 24-well plates coated with poly-D-lysine according to the man-
ufacturer’s instructions (Sigma-Aldrich). Endocytosis experiments were
performed essentially as described (8, 23). Briefly, triplicates of cells were
incubated in serum-free DMEM (supplemented with 2 mM glutamine)
containing 4000 cpm 125I-labeled Hp(2-2)–Hb for various time intervals at
37˚C. By the end of the incubation period, the medium was collected and
precipitated with 12.5% TCA to separate soluble fragments of degraded
Hp(2-2)–Hb from intact Hp(2-2)–Hb. Degradation of Hp(2-2)–Hb was
determined as the cell-mediated increment in TCA-soluble radioactivity in
the medium. Subsequently, cells were lysed with 0.5 M NaOH, and cell-
associated radioactivity was determined by counting the radioactivity of
the lysate.
Bacterial binding experiments
The bacterial strains Escherichia coli, Stenotrophomonas maltophilia,
Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Pseudo-
monas aeruginosa, Staphylococcus aureus, Enterococcus faecalis, and
Streptococcus agalactia were clinical isolates obtained from patients at
Odense University Hospital. The isolated bacteria were cultured on blood
agar plates under aerobic conditions at 37˚C for 48 h prior to the experi-
ment. Bacteria were harvested, washed twice in TBS, 5 mM CaCl2, 1%
The Journal of Immunology 2401









BSA, and finally resuspended to a concentration of 108 bacteria/ml. One
microgram recombinant CD163-L1 SRCR 1–12 or gp-340 (24) was added
to 108 bacteria before incubation for 2 h at 4˚C with gentle agitation.
Bacteria were pelleted by centrifugation at 3000 3 g for 5 min, and
supernatants were collected. The bacteria pellets were washed twice in
TBS, 5 mM CaCl2, 1% BSA, and finally resuspended in sample buffer.
Supernatants and cell pellets were analyzed by Western blotting using the
mAb anti–CD163-L1 (HG-Hyb1-3) or polyclonal rabbit anti–gp-340 (22)
essentially as described above.
Surface plasmon resonance analysis
Surface plasmon resonance (SPR) analysis of the binding of the Hp–Hb
complex to CD163 or CD163-L1 was carried out using a Biacore 3000
instrument (GE Healthcare). CD163 purified from human spleen was
immobilized, and sensorgrams were generated as described by Madsen
et al. (9). Purified recombinant CD163-L1 SRCR 1–12 was immobilized at
a concentration of 5 mg/ml in 10 mM sodium acetate, pH 4. The SPR
signal generated from the immobilized recombinant CD163-L1 protein
corresponded to 55 fmol protein/mm2. Sample and running buffer was 10
mM HEPES, 150 mM NaCl, 3.0 mM CaCl2, 1.0 mM EGTA, and 0.005%
Tween 20, pH 7.4.
Results
Recombinant CD163-L1 and mAbs
A schematic representation of full-length CD163-L1a (canonical
sequence) is shown in Fig. 1A. We expressed a number of dif-
ferent recombinant CD163-L1 variants in HEK293 cells, includ-
ing variants comprising the extracellular SRCR domains 1–7, the
entire ectodomain of CD163-L1 (SRCR 1–12), both fused to
a V5-6xhis epitope, and the two full-length splice variants CD163-
L1a and CD163-L1b. Recombinant CD163-L1 SRCR 1–7 was
used to develop mAbs resulting in two hybridomas HG-Hyb1-1
and HG-Hyb1-3 with non-overlapping epitopes (Fig. 1B). HG-
Hyb1-3 was applied in Western blotting, where it recognized
single protein bands in the unreduced supernatants of HEK293
cells stably transfected with either CD163-L1 SRCR 1–7 or
ectodomain cDNA (Fig. 1C). The two identified secreted protein
variants migrated with the approximate masses of 95 and 160 kDa,
respectively, which were equivalent to protein bands identified by
an anti-V5 Ab (data not shown). Western blot analysis of crude
cell lysates prepared from HEK293 cells stably transfected with
CD163-L1a or CD163-L1b cDNA gave rise to protein bands with
the expected molecular mass of ∼160 kDa (Fig. 1D). No cross-
reaction with HEK293 cells transfected with full-length CD163
cDNA (19) was observed. Fig. 1E summarizes the characteristics
of the two mAbs and the commercially available polyclonal Ab
used in this study.
Tissue distribution of CD163-L1 mRNA
We have previously demonstrated the presence of CD163-L1
mRNA in a number of human tissues by endpoint RT-PCR (1).
To extend and quantify these results, we performed a quantitative
RT-PCR (qRT-PCR) analysis on various human tissues using
TaqMan assays recognizing all annotated membrane-spanning
splice variants of CD163-L1 or CD163 (Fig. 2A). As expected,
expression of CD163-L1 and CD163 mRNA was detected in all
tested tissues. The CD163-L1 mRNA showed high expression in
tissues such as the spleen and the small intestine, whereas low
expression was observed in the brain, liver, and lung. In com-
parison, CD163 showed high expression in tissues such as the lung
and spleen but low expression in the brain. Absolute quantifica-
tion by qRT-PCR of CD163-L1a and CD163-L1b showed ex-
pression levels ranging from 30 to 1300 arbitrary units (AU) and
from undetected to 50 AU, respectively (Fig. 2B, 2C). The ex-
pression profile of CD163-L1a was indistinguishable from the
relative quantification by the assay detecting both splice variants
(Fig. 2A), whereas the expression profile of CD163-L1b showed
pronounced variations in several tissues. The relative abundance
of CD163-L1b mRNA accounted for 0–13% of the total CD163-
L1 mRNA (Fig. 2D).
Immunohistochemical localization of CD163-L1
The tissue expression of CD163-L1 was analyzed by immuno-
histochemical analysis on human tissues. The immunostaining of
CD163-L1 was compared with that of CD163 and with the myeloid
markers CD11c and CD68 in parallel tissue sections (Fig. 3A). The
analysis was performed using an affinity-purified polyclonal Ab
that specifically recognized recombinant full-length CD163-L1
expressed by HEK293 cells (Fig. 3B, 3C). CD163-L1 primarily
localized to lymphoid tissues such as the spleen, thymus, and
tonsils and to the small and large intestine. In the spleen, immu-
nostaining was observed in the red pulp macrophages and in cells
residing within the follicles, whereas no immunostaining was
observed in cells residing within the marginal zone. In the thymus,
CD163-L1 was present in medullary and cortical macrophages,
whereas the tonsils primarily showed immunostaining of peri-
follicular macrophages. Cells residing in the lamina propria of both
the small and the large intestines showed pronounced CD163-L1
FIGURE 1. Recombinant CD163-L1 and mAbs. (A) Schematic pre-
sentation of the domain organization of CD163-L1. (B) Direct ELISA
identifying HG-Hyb1-1 and HG-Hyb1-3 as mAbs with non-overlapping
epitopes. Biotinylated Abs were applied in serial dilutions onto CD163-L1
SRCR 1–7 coated microtiter plates preincubated with saturating amounts
of unlabeled Ab (100 ng/ml). (C) Western blot analysis (reduced/unre-
duced) of recombinant CD163-L1 SRCR 1–7 and ectodomain from
HEK293 supernatants. The blot was developed using the mAb HG-Hyb1-
3. (D) Western blot analysis (unreduced) of Triton X-100 cell lysates of
HEK293 cells transfected with full-length CD163-L1a, CD163-L1b, and
CD163 cDNA. The blots were developed using HG-Hyb1-3 (upper panel)
or a polyclonal rabbit anti-CD163 Ab (lower panel). (E) Functional
properties of the mAbs HG-Hyb1-1, HG-Hyb1-3, and the polyclonal af-
finity-purified anti–CD163-L1 Ab used in this study.
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immunostaining. In general, the tissue distribution of CD163-L1
in the lymphoid and intestinal tissues appeared similar to that of
CD163. However, the number of positive macrophages and the
signal intensity in the cells residing in the follicles of the spleen
were more pronounced for CD163-L1. Well-defined immuno-
staining of CD163-L1 and CD163 was also observed in macro-
phages residing in the chorionic villi of the placenta, whereas weak
staining was observed in these macrophages when stained for
CD11c and CD68. A prominent difference in the localization of
CD163-L1 and CD163 was observed in the liver and lung. Resident
tissue macrophages such as Kupffer cells in the liver and alveolar
macrophages in the lung showed pronounced immunostaining of
CD163, whereas no or only weak expression of CD163-L1 was
detected in these cells. The interstitial macrophages in the lung did,
however, show moderate CD163-L1 immunostaining. Absence of
CD163-L1+ cells was also observed in the cerebellum and in the
epidermis of the skin, suggesting that neither microglia nor Lang-
erhans cells express CD163-L1.
Western blotting of human tissue extracts
Triton X-100 lysates prepared from tissue samples of human
spleen, placenta, and small intestines were analyzed by Western
blotting using the mAb HG-Hyb1-3 (Fig. 4A). The Ab identified
a protein band with the approximate molecular mass of 160 kDa in
the unreduced state. No cross-reaction with CD163 (130 kDa) was
observed in any of the lysates. The identified protein showed the
same molecular mass as recombinant full-length CD163-L1a
expressed by HEK293 cells, suggesting that CD163-L1 exists as
a 160-kDa protein in human tissues. The identity of CD163-L1
was confirmed by mass spectrometry after immunoprecipitation
from placenta lysates using HG-Hyb1-1 or HG-Hyb1-3 (Fig. 4B).
To study the glycosylation level of CD163-L1, cell lysates con-
taining recombinant CD163-L1a or CD163-L1b were deglyco-
sylated using PNGase F (Fig. 4C). The deglycosylation caused
a reduction in the molecular mass from ∼160 to 135 kDa, sug-
gesting that several of the 16 potential N-linked glycosylation sites
residing within both CD163-L1a and CD163-L1b are indeed
glycosylated in vivo.
FACS analysis of peripheral blood leukocytes
The expression of CD163-L1 by freshly isolated human peripheral
blood leukocytes was determined by FACS analysis using the
mAbs HG-Hyb1-1 and HG-Hyb1-3 (Fig. 5). Both Abs clearly
recognized CD163-L1a expressed on HEK293 cells (Fig. 5A).
However, none of peripheral blood leukocytes showed a fluores-
cent signal above that of the isotype control, suggesting very low
FIGURE 2. CD163-L1 mRNA expression profile in human tissues. (A)
qRT-PCR analysis of CD163-L1 and CD163 mRNA expression in 10
different human tissues. Primers and probes were designed to recognize all
annotated splice variants of CD163-L1 and CD163. (B and C) Absolute
quantification of CD163-L1a and CD163-L1b mRNA expression by qRT-
PCR. (D) The relative abundance of CD163-L1b compared with the total
CD163-L1 mRNA. Absolute quantification of CD163-L1 splice variants
was estimated through assay-specific copy-number control dilution series
included in each run. Values are mean 6 SD of three independently per-
formed experiments.
FIGURE 3. Immunohistochemical an-
alysis of CD163-L1 in human tissues.
(A) Human tissues immunostained with
CD163-L1–specific affinity-purified poly-
clonal Ab (Protein Atlas ID: HPA015663)
compared with immunostaining of CD163
(clone 10D6) and the myeloid cell mar-
kers CD11c (clone 5D11) and CD68
(clone 10D6). The tissue sections pre-
dominantly showed immunostaining of
CD163-L1 in lymphoid tissues such as
the spleen, thymus, and tonsils and in
intestinal tissues such as the small in-
testines and colon. Original magnifica-
tion 3100 (spleen); 3200 (thymus, ton-
sil, colon, and small intestine); 3400
(placenta, liver, lung, cerebellum, and
skin). (B) Immunostaining of untrans-
fected as well as CD163-L1– and CD163-
transfected HEK293 cells. Original mag-
nification3400. (C) Western blot analysis
of HEK293 cells transfected with CD163
or CD163-L1 cDNA using the CD163-
L1–specific affinity-purified polyclonalAb.
No cross-reaction was observed between
the CD163-L1– or CD163-specific Abs.
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levels or absence of CD163-L1 on the surface of peripheral blood
leukocytes (Fig. 5B–D).
Expression of CD163-L1 mRNA in cultured monocytes,
macrophages, and dendritic cells
The immunohistochemical analysis of CD163-L1 showed a pro-
nounced staining of myeloid cells residing in the lymphoid and
intestinal tissues, whereas no expression of CD163-L1 was
detected by FACS analysis of peripheral blood leukocytes. This
discrepancy suggests that CD163-L1 expression is increased during
monocyte-to-macrophage differentiation. To address this, we per-
formed a qRT-PCR analysis of CD163-L1 mRNA expression from
freshly isolated CD14+ monocytes differentiated into macrophages
or dendritic cells in vitro. The CD163 mRNA expression was
assessed in parallel and used for comparison and as a control for
macrophage differentiation. Monocyte-derived macrophages were
obtained through culturing of freshly isolated peripheral blood
monocytes in the presence of M-CSF for 7 d. During the 7-d time
course, the expression of CD163-L1 mRNAwas increased 35-fold
(p , 1024), whereas the expression of CD163 mRNA was in-
creased 8-fold (p , 1023) (Fig. 6A). Monocyte-derived dendritic
cells were generated by culturing freshly isolated peripheral blood
monocytes for 6 d in the presence of GM-CSF and IL-4. The
monocyte-to-dendritic cell differentiation did not appear to in-
fluence the regulation of CD163-L1 mRNA expression, whereas
CD163 mRNA expression was reduced approximately 20-fold
(p , 1026) (Fig. 6B). It is noteworthy that only the CD163-L1a
splice variant was detected in the freshly isolated and cultured
CD14+ monocytes (data not shown), suggesting that CD163-L1b
is differentially expressed.
Regulation of CD163-L1 by inflammatory mediators
Myeloid markers of differentiation are often also regulated by
pro- or anti-inflammatory stimuli. To analyze this further, we per-
formed a qRT-PCR analysis of the monocyte-derived macrophages
(Fig. 6A, day 7) cultured for an additional 24 h in the presence of
various inflammatory mediators. Proinflammatory mediators such
as LPS, IFN-g, and TNF-a, associated with classical activation of
macrophages, resulted in a significant downregulation of CD163-
L1 (Fig. 6C). In particular, LPS combined with IFN-g resulted in a
pronounced decrease in CD163-L1 expression (p , 1026). A less
prominent but significant downregulation of CD163-L1 was also
FIGURE 4. Identification of CD163-L1 as a 160-kDa glycoprotein in
tissues. (A) Western blot analysis (unreduced) of Triton X-100 tissue
lysates from spleen, placenta, and small intestine, together with cell lysates
of untransfected and CD163-L1a transfected HEK293 cells. The blot was
developed using the mAb HG-Hyb1-3. (B) Silver staining of CD163-L1
immunoprecipitated from Triton X-100 placenta lysate using immobilized
HG-Hyb1-1 or HG-Hyb1-3. The identity of CD163-L1 was verified by
mass spectrometry. (C) Western blot analysis (unreduced) of PNGase F-
treated Triton X-100 lysates of CD163-L1a and CD163-L1b transfected
HEK293 cells. The blot was developed using HG-Hyb1-3.
FIGURE 5. Flow cytometric analysis of freshly isolated peripheral
blood leukocytes. (A) Histogram showing CD163-L1 staining of HEK293
cells transfected with CD163-L1a cDNA using the mAbs HG-Hyb1-1
and HG-Hyb1-3 versus an isotype control. (B–D) Histograms of isolated
granulocyte, lymphocyte, and monocyte populations. No fluorescence
signal above the isotype control was observed in any of the analyzed cell
populations.
FIGURE 6. CD163-L1 mRNA expression in cultured monocytes,
macrophages, and dendritic cells. The relative expression of CD163-L1
mRNAwas determined by qRT-PCR and compared with the expression of
CD163 mRNA. (A) CD14+ peripheral blood monocytes cultured in vitro
with M-CSF for 7 d, generating monocyte-derived macrophages. (B)
CD14+ peripheral blood monocytes cultured in vitro with GM-CSF and
IL-4 for 6 d, generating monocyte-derived dendritic cells. (C) Monocyte-
derived macrophages stimulated with the inflammatory mediators IL-4,
IL-13, LPS, IFN-g, LPS/IFN-g, and TNF-a. (D) Monocyte-derived mac-
rophages stimulated with the inflammatory mediators IL-6, IL-10, and
dexamethasone. Measurements are mean 6 SD of five independently
performed experiments. *p , 0.05, **p , 0.005, ***p , 0.0005.
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observed after stimulation with the proinflammatory mediators
IL-4 and IL-13 both associated with alternative activation of
macrophages (p , 1023 and p , 0.05, respectively). Stimulation
with the cytokines IL-6 and IL-10 both resulted in a significant
upregulation of CD163-L1 (Fig. 6D). IL-6, a pleiotropic cytokine,
resulted in a 3-fold upregulation of CD163-L1 (p , 0.05), and
the anti-inflammatory cytokine IL-10 resulted in a 6-fold up-
regulation of CD163-L1 (p , 0.05). Surprisingly, we found that
treatment with glucocorticoid, which is also known to have
strong anti-inflammatory properties and to upregulate CD163,
resulted in a more than 2-fold downregulation of CD163-L1
(p , 0.05).
Subcellular distribution of the CD163-L1 splice variants
Both CD163-L1a and CD163-L1b are predicted to be membrane
proteins. To investigate this, we analyzed HEK293 cells trans-
fected with full-length CD163-L1a or CD163-L1b cDNA by im-
munofluorescence confocal microscopy. Cells transfected with
CD163-L1a cDNA showed a distinct cell surface staining, whereas
cells transfected with CD163-L1b cDNA displayed a substantially
lower degree of cell surface staining (Fig. 7A, upper panel). This
difference in fluorescence intensity was not evident when the same
cells were permeabilized (Fig. 7A, lower panel). Western blot
analysis of crude cell lysates prepared from the transfected HEK293
cells showed similar expression levels of CD163-L1a and CD163-
L1b (Fig. 7D), suggesting that the pronounced difference in cell
surface staining observed between CD163-L1a and CD163-L1b
was due to a difference in the cellular distribution of the two splice
variants. To confirm and quantify this apparent difference in sub-
cellular distribution, we performed a flow cytometric analysis of the
HEK293 cells expressing the splice variants. A clear difference in
fluorescence intensity was observed between fixed, surface-stained
CD163-L1a– and CD163-L1b–expressing cells (Fig. 7B), which
was diminished upon permeabilization of the cells (Fig. 7C). Gentle
fixation did not significantly affect cell surface staining, suggesting
that the epitope recognized by the mAb and the cell membrane
integrity were intact (data not shown). The geometric means of
the measured fluorescent signals from the surface-stained and per-
meabilized cells were used to quantify the cellular distribution
of the splice variants (Fig. 7E). Approximately 25% of the total
amount of CD163-L1a was estimated to be cell surface associated,
whereas less than 3% of CD163-L1b was associated with the cell
surface.
Internalization of CD163-L1
The endocytic properties of CD163-L1 were initially analyzed by
confocal fluorescence microscopy after cross-linking with mAbs.
HEK293 cells expressing CD163-L1a were cell surface stained
with Alexa 488-conjugated HG-Hyb1-3 at 4˚C, and unbound Ab
was removed by washing. Incubation was then continued for 20 min
at either 4˚C or 37˚C. Cells kept at 4˚C showed a well-defined cell
surface staining of CD163-L1, whereas cells incubated at 37˚C
showed a pronounced intracellular CD163-L1 staining (Fig. 8A).
To assess whether the observed internalization of CD163-L1
resulted from the Ab-mediated cross-linking of CD163-L1, a par-
allel experiment was performed using the corresponding Fab
fragment of HG-Hyb1-3 (Fig. 8B). CD163-L1 ligation using
Alexa 488-conjugated Fab fragment resulted in the internalization
of the Fab fragment, which was visually indistinguishable from
the internalization of the intact Ab. To quantify the endocytic
properties of CD163-L1, we performed a time-course experiment
by flow cytometry. The cell surface distribution of CD163-L1a,
visualized by intact or Fab HG-Hyb1-3, was found to decrease
rapidly over a time course of 10 min reaching a steady plateau of
∼25% (Fig. 8C). A similar decrease was not observed using Alexa
488-conjugated Abs, demonstrating that the decrease in cell sur-
face association was not due to Ab disassociation but due to
internalization of both intact IgG and the corresponding Fab
fragment. To investigate the possible mechanism behind the in-
ternalization of CD163-L1, we performed site-directed mutagen-
esis of the classical di-leucine internalization motif residing in
the cytoplasmic tail of CD163-L1. However, substitution of both
leucines with alanines did not appear to influence the internali-
zation of CD163-L1 (Fig. 8D). We found, however, that the
presence of sucrose or chlorpromazine, both inhibitors of clathrin-
mediated endocytosis, resulted in an almost complete inhibition of
wild-type CD163-L1a internalization, whereas no inhibition was
observed in the presence of nystatin, an inhibitor of lipid raft/
caveolae-mediated endocytosis (Fig. 8E).
CD163 has previously been demonstrated to mediate the
endocytosis and degradation of 125I-labeled Hp–Hb complexes
(8, 23). Thus, to demonstrate directly the endocytic capacity of the
FIGURE 7. Subcellular distribution of the CD163-L1 splice variants.
(A) Analysis of CD163-L1 splice variants by confocal microscopy (orig-
inal magnification 3200). Cell surface-stained and permeabilized cells
were analyzed using HG-Hyb1-1 and FITC-conjugated polyclonal F(ab9)2
goat anti-mouse Ig. (B and C) Flow cytometric analysis of cell surface-
stained and permeabilized cells using HG-Hyb1-1 and FITC-conjugated
polyclonal F(ab9)2 goat anti-mouse Ig. The experiments shown are repre-
sentative of three independently performed experiments. (D) Semiquanti-
tative Western blot analysis of the expression levels of CD163-L1 splice
variants expressed in HEK293 cells. The blot was developed using HG-
Hyb1-3 standardized to GAPDH. (E) Statistical analysis of the subcellular
distribution of the CD163-L1 splice variants. Measurements are mean 6
SD of three independently performed experiments.
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CD163-L1 tail, we performed an equivalent experiment using
a recombinant CD163–CD163-L1 hybrid protein comprising the
extracellular and transmembrane regions of CD163 (aa 1–1067)
linked to the cytoplasmic part of CD163-L1a (aa 1383–1453).
The endocytic capacity and degradation of the Hp–Hb complexes,
as well as the expression level and cell surface distribution of the
CD163–CD163-L1 fusion protein, was found to be equivalent to
that of wild-type CD163 (Fig. 8F–H).
CD163 lacks bacterial binding activity in vitro and is
functionally distinct from CD163
Several members of the SRCR superfamily such as SR-AI, CD163,
gp-340, MARCO, CD5, CD6, and Spa function as pattern rec-
ognition receptors with the ability to bind pathogen-associated
molecular patterns (12–18). We investigated the ability of re-
combinant CD163-L1 ectodomain to bind to a range of clinical
isolates of both Gram-positive and Gram-negative bacteria in a
pull-down experiment (Fig. 9A). gp-340, known to bind directly
to different bacterial strains (14, 25–27), was included as an ex-
perimental control. gp-340 bound to all tested bacterial strains as
indicated by its presence in the bacterial pellets. In contrast, no
recombinant CD163-L1 protein was detected in any of the bac-
terial pellets, showing that recombinant CD163-L1 does not bind
to these bacteria.
The strong resemblance to the Hp–Hb receptor CD163 led us
to investigate the possible interaction between CD163-L1 and
the Hp–Hb complex. Using CD163 as a positive control, we
performed an SPR analysis and, as expected, demonstrated a high-
affinity binding between immobilized CD163 and both the Hp1-1
and Hp2-2 phenotypes of haptoglobin in complex with hemo-
globin as reported by Kristiansen et al. (8). Similar high-affinity
binding was not observed to recombinant CD163-L1 ectodomain
regardless of the haptoglobin type or the presence of hemoglobin
(Fig. 9B, 9C). In agreement with these findings, CD163-L1–
transfected HEK293 cells were unable to mediate internalization
of Hp–Hb (data not shown).
FIGURE 8. The endocytic properties of CD163-L1. (A and B) Confocal fluorescence microscopy of CD163-L1 internalization. HEK293 cells transfected
with CD163-L1a were incubated with Alexa 488-conjugated HG-Hyb1-3 (IgG or Fab), then washed to remove unbound Ab before incubation was
continued for 20 min at 4˚C or 37˚C. Cells were counterstained with Alexa 633-conjugated wheat germ agglutinin and stained with DAPI before analysis.
Original magnification 3200. (C–E) Flow cytometric analysis of CD163-L1 internalization. HEK293 cells transfected with CD163-L1a cDNA were in-
cubated with Alexa 488-conjugated HG-Hyb1-3 (IgG/Fab) or unlabeled HG-Hyb1-3 (IgG/Fab), then washed to remove unbound Ab before incubation was
continued at 4˚C or 37˚C. Internalization was followed over a time course of 20 min. Cells were subsequently stained with FITC-conjugated polyclonal
F(ab9)2 goat anti-mouse Ig before analysis. (C) Internalization of CD163-L1a using Alexa 488-conjugated and unlabeled Abs. (D) Internalization of
CD163-L1a (wild-type) versus CD163-L1a (LLmut). (E) Internalization of CD163-L1a in the presence of chlorpromazine (100 mM), sucrose (0.4 M), or
nystatin (40 mM), known inhibitors of internalization. (F) Western blot analysis of lysate from HEK293 cells transfected with CD163 or CD163–CD163-L1
fusion cDNA. The primary Ab used was a rabbit polyclonal anti-CD163 Ab. (G) Confocal microscopy of cell surface-stained HEK293 cells transfected with
either CD163 wild-type or CD163–CD163-L1 fusion cDNA. Cells were stained using rabbit polyclonal Ab against CD163 and Alexa 488-labeled anti-
rabbit Ab, in addition to staining with DAPI. Original magnification 3200. (H) Cell association and degradation of 125I-labeled Hp–Hb complexes in
untransfected HEK293 cells or cells transfected with either CD163 wild-type or CD163–CD163-L1 fusion cDNA.
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We have previously cloned and characterized CD163-L1 (M160) as
a type I transmembrane SRCR molecule, expressed by cells of
myeloid origin (1), yet little is known about the expression pattern
and function of CD163-L1.
In the current report, we characterized the expression of
CD163-L1 on peripheral blood leukocytes by flow cytometry.
Through the use of two mAbs with different CD163-L1 epitopes,
we showed that the expression of CD163-L1 was absent or
negligible on the peripheral blood leukocytes. In contrast, the
expression of CD163 on the monocyte population has been re-
ported to vary from a few to 99% depending on the experimental
conditions and the Abs used (28–32). MAC2-158, which rec-
ognizes the first SRCR domain of CD163, is a well-characterized
Ab that stains more than 80% of the monocyte population pos-
itive for CD163 (32).
To further characterize the expression of CD163-L1, we isolated
peripheral blood monocytes, and we could demonstrate that the
expression of CD163-L1 mRNAwas increased 35-fold during the
in vitro-driven cytokine differentiation of monocytes to macro-
phages, whereas the mRNA levels appeared unchanged during
the differentiation of monocytes to dendritic cells. Thus, alto-
gether these results clearly suggest that CD163-L1 is a genuine
monocyte-to-macrophage differentiation marker.
To extend these findings, we compared the expression pattern of
CD163-L1 to that of CD163 and the myeloid markers CD11c and
CD68 by immunohistochemical analysis of various human tissues.
We observed a predominant immunostaining for CD163-L1 in
myeloid cells residing in lymphoid tissues such as the spleen,
thymus, and tonsils and in intestinal tissues such as the small
intestine and colon. In the spleen, white- as well as red-pulp
macrophages were CD163-L1+, whereas marginal-zone macro-
phages were negative. To our surprise, we saw low or absence of
staining in long-lived tissue-specific macrophages such as Kupffer
cells, alveolar macrophages, and microglia, which stained positive
for the other myeloid markers. Also, dendritic cells like Langer-
hans cells residing in the epidermis appeared to be negative. This
staining pattern indicates that CD163-L1 is a marker for a special
subset of macrophages and not a general macrophage marker.
Finally, we usedWestern blot analysis of solubilized tissues from
placenta, spleen, and small intestine to verify the presence and the
molecular mass of CD163-L1 in tissues.We identified a single band
of 160 kDa in all tested tissues, which was identical to the band
found in HEK293 cells expressing full-length CD163-Ll, and we
verified the identity of CD163-L1 in the bands by mass spec-
trometry. The calculated molecular mass of full-length CD163-L1a
is 154.5 kDa without the signal peptide, and we showed that
deglycosylation of CD163-L1 reduced the molecular mass to ap-
proximately this level. Thus, we are confident that the tissue
staining that we detected with our Abs indeed represents the full-
length CD163-L1 gene product.
We next studied the regulation of CD163-L1 in monocyte-
derived macrophages driven in different directions by cytokines
and other inflammatory mediators. LPS, which is the canonical
innate immune stimulus that drives macrophages in the direction of
classically activated macrophages (M1-polarized macrophages)
(33, 34), significantly downregulated the expression of CD163-L1,
and there was an additive effect of IFN-g, the key cytokine driving
macrophages further down that lane. TNF-a, another inducer
of classically activated macrophages, also reduced the level of
CD163-L1. Stimulation with IL-13 and especially IL-4, both of
which lead to alternatively activated macrophages (M2-polarized
macrophages) (33–36), also reduced the CD163-L1 expression. In
contrast to this, we observed a clear upregulation of CD163-L1
expression when the monocyte-derived macrophages were stim-
ulated with IL-10, which leads to a regulatory/anti-inflammatory
macrophage phenotype (37). We observed, however, that stimu-
lation with dexamethasone, which also directs into a regulatory/
anti-inflammatory macrophage phenotype, resulted in a downreg-
ulation of CD163-L1. This could indicate that CD163-L1 is a
marker for a subset of regulatory macrophages. This is consistent
with the view that the M1/M2 classification of macrophage phe-
notypes is not an exhaustive description of the many different
macrophage phenotypes present in the different tissue milieus (34,
35, 37).
Similar regulation of expression during monocyte differentia-
tion to macrophages and subsequent regulation by inflammatory
mediators has been reported for CD163 (38, 39). The major dif-
ference between the regulations of expression between the two
molecules is that dexamethasone is a strong inducer of CD163
(38, 40, 41). CD163 is well characterized as the Hp–Hb receptor
(8–10) and has been proposed to function in the innate immune
response and resolution of inflammation. Degradation of Hp–Hb
has been shown to mediate the release of metabolites with strong
anti-oxidative and anti-inflammatory effects (42), and binding of
Hp–Hb complexes to CD163 has been shown to mediate the direct
secretion of IL-10 (43). In contrast, other reports have shown that
cross-linking of CD163 with mAbs, as well as interaction with
FIGURE 9. Binding of recombinant CD163-L1 ectodomain to whole
bacteria and Hp–Hb. (A) Recombinant gp-340 and CD163-L1 binding to
nine clinical isolates in the presence of 5 mM CaCl2. Bacteria were in-
cubated with recombinant protein, washed, and subjected to Western blot
analysis. Recombinant protein was detected in supernatants and pellets
with anti–gp-340 polyclonal Ab and HG-Hyb1-3, respectively. (B and C)
SPR analysis of binding of Hp–Hb to CD163 and CD163-L1 ectodomain.
The measurements were carried out at hemoglobin (Hb) concentrations of
0, 25, and 50 mg/ml in the absence or presence of 0, 25, or 50 mg/ml
haptoglobin (Hp; phenotype 1-1 or 2-2).
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bacteria, mediates the release of proinflammatory cytokines (12,
41, 44). Thus, CD163 appears to function as an immune modu-
lator with the ability to suppress as well as stimulate the innate
immune response. The many similarities to CD163 with regard
to tissue distribution and regulation, combined with induction of
expression by the acute-phase inflammatory mediator IL-6, sug-
gests that CD163-L1 in a similar way may function in the mod-
ulation of the innate immune response.
We have identified two cytoplasmic splice variants for CD163-L1:
the full-length variant (CD163-L1a) with a cytoplasmic tail of 71
residues and the short-tail variant (CD163-L1b) of 39 residues (1).
CD163-L1a contains three potential phosphorylation sites, which
are lost in CD163-L1b due to alternative splicing of exon 18.
However, both splice variants contain the di-leucine internalization
motif. In agreement with our previous report where we used con-
ventional endpoint RT-PCR, our current qRT-PCR analyses iden-
tified CD163-L1a as the predominant CD163-L1 mRNA species in
various human tissues. When expressed in HEK293 cells, CD163-
L1a was found to be cell surface associated, whereas CD163-L1b
appeared mainly in the intracellular compartments. The functional
implication of these pronounced quantitative differences in ex-
pression and subcellular distribution of the two splice variants are
unknown. Similar differences in splice variant distribution have
been reported for CD163 (23), underlining the many observed
similarities between CD163 and CD163-L1.
The resemblance to CD163 and the presence of a putative di-
leucine internalization motif in the cytoplasmic tail of CD163-L1
led us to examine the endocytic properties of CD163-L1. By use
of confocal microscopy, flow cytometry, and endocytosis assays, we
could demonstrate that CD163-L1 indeed functions as an endocytic
receptor with an endocytic capacity equivalent to that of CD163.
Moreover, the ability of both intact IgG and Fab fragment to me-
diate internalization of CD163-L1 suggests that CD163-L1 is con-
stitutively internalized independently of ligand ligation.
Constitutive internalization has been described for CD163,
whereas the internalization of CD5 appears to be somewhat de-
pendent on ligand ligation (45, 46). Nevertheless, both CD163 and
CD5 contain an internalization motif of the type YXXf (where f
represents a bulky hydrophobic residue), which has been shown
to be associated with clathrin-mediated endocytosis (46, 47). The
presence of sucrose or chlorpromazine, which are inhibitors of
clathrin-mediated endocytosis (48, 49), almost completely abolished
the internalization of CD163-L1, suggesting that internalization of
CD163-L1 in a similar way is mediated through clathrin-coated pits.
However, the mechanisms resulting in this internalization seem
to differ from those of CD163 and CD5, as the cytoplasmic tails
of CD163-L1 do not include the YXXf internalization motif.
Surprisingly, removal of the putative di-leucine internalization motif
in the cytoplasmic tail of CD163-L1 by site-directed mutagenesis
did not influence the internalization of CD163-L1.
Many of the members of the SRCR group B family that show
high homology to CD163-L1, including gp-340, CD5, CD6, and
Spa, function as pattern recognition receptors by binding to intact
microorganisms (16–18, 25). The peptide sequence involved in the
microbial binding has been identified for several of these mole-
cules, and CD163-L1 includes the consensus sequence in several
of the SRCR domains. Nevertheless, we were unable to demon-
strate binding to a series of clinical isolates of bacteria that in
parallel experiments bound to gp-340. Likewise, we were not able
to demonstrate binding between CD163-L1 and the Hp–Hb
complex as described for CD163 (8). Other attempts to identify
possible ligands for CD163-L1 including various coprecipitation
experiments and screening of peptide libraries have to date been
negative. Future attempts to elucidate the possible ligands for
CD163-L1 include mass spectrometry combined with biotinylated
recombinant extracellular CD163-L1 as bait for endogenous as
well as microbial ligands. Furthermore, we will use immobilized
anti–CD163-L1 Abs to study the possible signaling and/or mod-
ulation responses mediated through CD163-L1.
In the current report, we demonstrate that CD163-L1 is a
monocyte-to-macrophage differentiation marker, which is absent
from the main classes of long-lived resident tissue macrophages
but present on the majority of other tissue macrophages. In vitro
stimulation of monocyte-derived macrophages suggests that many
of these cells may be of the regulatory macrophage phenotype.
CD163 has been suggested as a diagnostic tool and as a potential
target for immunotherapy in malignant diseases (50–55). Whether
CD163-L1 in a similar way could function as a diagnostic tool or
as a potential target for immunotherapy remains to be defined.
However, one could speculate that the absence of expression of
CD163-L1 on, for example, Kupffer cells and blood monocytes
could prove beneficial in immunotherapy to minimize the unin-
tended adverse drug delivery side effects often associated with
chemotherapeutic agents.
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